RogCon Biosciences

RogCon Biosciences Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $1.14M
Latest Deal Amount

RogCon Biosciences General Information


Developer of novel therapeutics intended to treat children suffering from SCN2A mutations. The company's therapeutics treats genetic epilepsy and other genetic diseases, enabling clinicians to take deliberate action on mutation related diseases.

Contact Information

Formerly Known As
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 5251 Lagorce Drive
  • Miami Beach, FL 33140
  • United States
+1 (305) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RogCon Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 03-Apr-2017 $1.14M 00.000 000.00 Completed Generating Revenue

RogCon Biosciences Cap Table

To view RogCon Biosciences‘s complete cap table, request access »
Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.0 00.00 00.00 00 00.00 00

RogCon Biosciences Executive Team (3)

Name Title Board Seat Contact Info
Alex Nemiroff Co-Founder, President, Chief Executive Officer & Board Member
Kelley Dalby Co-Founder, Senior Vice President & Board Member
Steven Petrou Co-Founder

RogCon Biosciences Board Members (2)

Name Representing Role Since
Alex Nemiroff RogCon Biosciences Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Kelley Dalby RogCon Biosciences Co-Founder, Senior Vice President & Board Member 000 0000

Ready to get started?

Request a free trial